[["BRAF(V600E) mutation", "exerts", "an essential oncogenic function in many tumors"], ["BRAF(V600E) inhibitors", "are available", "but lack of response has been frequently observed"], ["short-term primary cell cultures", "were established", "of human metastatic/recurrent BRAF(V600E)-PTC, intrathyroidal BRAF(V600E)-PTC, and normal thyroid"], ["early intervention model", "was generated", "of human BRAF(V600E)-PTC orthotopic mouse"], ["metastatic BRAF(V600E)-PTC cells", "elicit", "paracrine-signaling"], ["paracrine-signaling", "triggers", "migration of pericytes, blood endothelial cells and lymphatic endothelial cells"], ["metastatic BRAF(V600E)-PTC cells", "show", "a higher rate of invasion compared to BRAF(WT)-PTC cells"], ["vemurafenib therapy", "significantly suppresses", "aberrant functions in non-metastatic BRAF(V600E)-PTC cells"], ["vemurafenib therapy", "is lesser effective", "in metastatic BRAF(V600E)-PTC cells compared to vehicle treatment"], ["results", "concur with", "down-regulation of tumor microenvironment-associated pro-metastatic molecules"], ["no effects", "are observed", "in BRAF(WT)-PTC and NT cells"], ["vemurafenib", "delays", "tumor growth in orthotopic BRAF(WT/V600E)-PTC mice"], ["high copy number gain of MCL1", "is identified", "in metastatic BRAF(V600E)-PTC cells"], ["loss of CDKN2A", "is associated with", "resistance to vemurafenib treatment"], ["combined vemurafenib therapy with BCL2/MCL1 inhibitor", "increases", "metastatic BRAF(V600E)-PTC cell death"], ["combined vemurafenib therapy", "ameliorates", "response to vemurafenib treatment compared to single agent treatment"], ["short-term PTC and NT cultures", "offer", "a predictive model for evaluating therapeutic response in patients with PTC"], ["PTC pre-clinical model", "suggests", "combined targeted therapy might be an important therapeutic strategy for metastatic and refractory BRAF(V600E)-positive PTC"]]